Genovis AB Stocks

Genovis AB (publ.) is a Swedish biotechnology firm that invents, develops, and commercializes advanced enzymatic tools crucial for drug discovery and development. These innovative solutions primarily cater to the pharmaceutical and medical device industries. The company's extensive product portfolio features a variety of highly specific enzymes designed for the precise modification and analysis of antibodies, particularly immunoglobulins (IgG). This includes several proteases like FabALACTICA, which specifically digests human IgG1; FabRICATOR, an enzyme that primarily cleaves the IgG hinge region; and FabRICATOR Z, tailored for digesting mouse IgG2a and IgG3 to yield uniform F(ab')2 and Fc fragments. Other proteolytic tools encompass FabULOUS (SpeB), another enzyme for IgG hinge digestion; GingisKHAN, a cysteine protease that targets human IgG1 at a specific site above the hinge; and GingisREX, a cysteine protease that cleaves peptide bonds C-terminally to arginine residues. Beyond these fragmentation tools, Genovis also specializes in enzymes for glycan modification and analysis. Their offerings include IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that precisely hydrolyzes N-linked glycans in the Fc-region of native IgG, as well as IgGZERO LE, which acts on complex type N-glycans. For deglycosylation of Fc-glycans, they provide deGlycIT, an agarose bead-immobilized version of IgGZERO. Further glycan-related products include GlycINATOR, an endoglycosidase also from Streptococcus pyogenes that hydrolyzes all glycoform structures, and GlycINATOR (EndoS2), which specifically targets glycans at the Fc glycosylation site of IgG. Additionally, Genovis offers SialEXO, a sialidase product for the removal and analytical study of sialic acids, alongside other enzymes for O-glycans. Complementing its enzymatic reagents, the company provides GlyCLICK, a proprietary site-specific conjugation technology for IgG, which leverages enzymatic remodeling of Fc glycans and click chemistry. They also offer specialized antibody fragmentation services and facilitate product purchases via their online store. Genovis serves a global clientele, including pharmaceutical, biotechnology, contract research (CRO), and contract manufacturing (CMO) organizations across Sweden, Europe, North America, and Asia. A key strategic partnership exists with Waters Corporation. Established in 1999, Genovis is headquartered in Lund, Sweden.